Kriya Therapeutics Secures $320M to Advance Gene Therapy Pipeline

Kriya Therapeutics, a company focused on developing gene therapies for chronic diseases, has announced a successful Series D funding round, raising a significant $320 million. This substantial investment will enable Kriya to accelerate its clinical trials across various therapeutic areas and further enhance its research and development (R&D) and manufacturing capabilities.

The funding round was jointly led by Premji Invest and Patient Square Capital, with participation from a consortium of life sciences and technology investors. This diverse group of investors underscores the strong confidence in Kriya's approach and its potential to address unmet medical needs.

Kriya's pipeline is centered on gene therapies designed to deliver treatment directly to the affected tissues in chronic conditions. The company's therapeutic focus includes:

• Thyroid eye disease
• Geographic atrophy
• Trigeminal neuralgia
• Type 1 diabetes
• Metabolic-associated steatohepatitis (MASH)

A key differentiator for Kriya is its integrated R&D and manufacturing platform. This framework is designed to establish new industry standards for gene therapy purity and cost-effectiveness, addressing critical challenges in the field.

Key Takeaways:

• Significant Funding: Kriya Therapeutics raises $320 million in Series D funding.
• Focus on Chronic Diseases: The company is developing gene therapies targeting a range of chronic conditions.
• Integrated Platform: Kriya's integrated R&D and manufacturing platform aims to improve gene therapy development and production.

Akshay Rai from Premji Invest will join Kriya's board of directors, bringing valuable expertise in healthcare and biotech investing.